1. Redox responsive xylan-SS-curcumin prodrug nanoparticles for dual drug delivery in cancer therapy.
- Author
-
Sauraj, Vinay Kumar, Kumar B, Priyadarshi R, Deeba F, Kulshreshtha A, Kumar A, Agrawal G, Gopinath P, and Negi YS
- Subjects
- Antineoplastic Combined Chemotherapy Protocols pharmacology, Curcumin chemistry, Curcumin pharmacology, Disulfides chemistry, Drug Liberation, Drug Stability, Fluorouracil administration & dosage, Fluorouracil pharmacokinetics, HT29 Cells, Hemolysis drug effects, Humans, Nanoparticles administration & dosage, Neoplasms drug therapy, Oxidation-Reduction, Particle Size, Prodrugs administration & dosage, Prodrugs chemistry, Spectroscopy, Fourier Transform Infrared, Stearic Acids chemistry, Xylans chemistry, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Curcumin administration & dosage, Drug Delivery Systems methods, Nanoparticles chemistry
- Abstract
Chemotherapeutic agents with different anticancer mechanisms could enhance therapeutic effect in cancer therapy by their combined application. In this study, redox-sensitive prodrug nanoparticles based on Xyl-SS-Cur conjugate were developed for co-delivery of curcumin and 5-FU in cancer therapy. The Xyl-SS-Cur conjugate was synthesized via covalent conjugation of curcumin to xylan through a disulphide (-S-S-) linkage. The Xyl-SS-Cur conjugate could self-assemble in aqueous medium into nanoparticles and the lipophilic 5-fluorouracil-stearic acid (5-FUSA) prodrug was encapsulated into the hydrophobic core of Xyl-SS-Cur NPs through dialysis membrane method. The obtained Xyl-SS-Cur/5-FUSA NPs had an appropriate size (∼217 ± 2.52 nm), high drug loading of curcumin (∼ 31.4 wt%) and 5-FUSA (∼ 11.8 wt%) and high stability. The interaction of Xyl-SS-Cur/5-FUSA NPs with blood components was investigated by hemolysis study. The cytotoxicity study demonstrated that Xyl-SS-Cur/5-FUSA NPs induced higher cytotoxicity than free drugs against the Human colorectal cancer cells (HT-29, HCT-15). These results indicate that Xyl-SS-Cur/5-FUSA NPs can serve as a promising drug delivery system in cancer therapy., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF